20913 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria Streptokinase
CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#2CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#3CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#4CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#5CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#6Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#7CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#8METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY
#9Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#10METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY
#11Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#12Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#13Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#14Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factor
#15Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#16Methods and pharmaceutical compositions for the treatment of ischemic conditions
#17Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#18Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
#19Protein fusion constructs possessing thrombolytic and anticoagulant properties
#20ADMINISTRATION OF ENOXOPARIN SODIUM TO PATIENTS 75 YEARS AND OLDER WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
#21DICHLORACETATE IN COMBINATION WITH CLINICALLY HIGH LEVELS OF CARDIOPROTECTIVE OR HEMODYNAMIC DRUGS
#22Keratin biomaterials for treatment of ischemia
#23Polysaccharide-protein conjugates reversibly coupled via imine bonds
#24Administration of Enoxoparin Sodium to Patients 75 Years and Older With ST-Segment Elevation Myocardian Infarction
#25Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow
#26DICHLOROACETATE IN COMBINATION WITH CLINICALLY HIGH LEVELS OF CARDIOPROTECTIVE OR HEMODYNAMIC DRUGS
#27NEUROPROTECTION BY BLOOD FLOW STABILIZATION
#28Kappam-conopeptides as organ protectants
#29Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
#30Formulations for the rectal administration of thrombolytically-active agents
#31Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs
#32Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses
#33Ointment wound spray
#34Administration of enoxaparin sodium to patients 75 years and older with ST-segment elevation myocardial infarction
#35Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses
#36Method for reducing obstructive hydrocephalus
#37Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
#38Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
#39Administration of enoxoparin sodium to patients 75 years and older with ST-segment elevation myocardial infarction
#40Lung volume reduction using glue composition
#41Lung volume reduction using glue compositions
#42Targeting damaged lung tissue
#43Ointment wound spray